Central Library

Normal view MARC view ISBD view

Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene [electronic resource] / by Amita Kashyap, D. Bujamma, Naresh Babu M.

By: Kashyap, Amita [author.].
Contributor(s): Bujamma, D [author.] | Babu M, Naresh [author.] | SpringerLink (Online service).
Material type: materialTypeLabelBookSeries: SpringerBriefs in Applied Sciences and Technology: Publisher: Singapore : Springer Singapore : Imprint: Springer, 2015Description: VII, 72 p. 40 illus., 39 illus. in color. online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9789814585088.Subject(s): Engineering | Cancer research | Health informatics | Bioinformatics | Applied mathematics | Engineering mathematics | Computational intelligence | Biomedical engineering | Engineering | Computational Intelligence | Computational Biology/Bioinformatics | Cancer Research | Biomedical Engineering | Health Informatics | Appl.Mathematics/Computational Methods of EngineeringAdditional physical formats: Printed edition:: No titleDDC classification: 006.3 Online resources: Click here to access online
Contents:
Introduction -- Review of Literature -- Materials and Methods (Tools and Databases) -- Flowchart -- Conclusion.-References.
In: Springer eBooksSummary: Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies. This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.
    average rating: 0.0 (0 votes)
No physical items for this record

Introduction -- Review of Literature -- Materials and Methods (Tools and Databases) -- Flowchart -- Conclusion.-References.

Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies. This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.

There are no comments for this item.

Log in to your account to post a comment.